This trial is evaluating whether IVLCM tethered capsule will improve 1 primary outcome in patients with Barrett Esophagus. Measurement will happen over the course of 5 months.
This trial requires 30 total participants across 2 different treatment groups
This trial involves 2 different treatments. IVLCM Tethered Capsule is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Patients with BE who present early and with few symptoms can safely undergo non-surgical treatment. Patients with more advanced disease and symptoms or other serious comorbidities are likely to qualify for surgical intervention.
The effectiveness of managing Barrett's esophagus is limited to preventing it from becoming advanced or cancerous. Although not curable, Barrett's esophagus can be managed successfully with regular endoscopic surveillance and a standard regimen of medications to prevent Barrett's esophagus recurrence.
The common side effects of ITCM are nausea and vomiting. Severe side effects occurred <10%; therefore, these side effects are not considered a justification for removing the device. If the side effects are moderate or severe, a doctor may request that all patients return to the clinic for further assessment. The patients need to be informed that severe side effects are <10%. The ITCM can effectively relieve symptoms in some cases. However, most patients require a more complex treatment.
Signs and symptoms of BE include heartburn, esophageal reflux and dysphagia with symptoms worsening with meals and after lying down or lying flat. The diagnosis can only be made by esophageal biopsy. A combination of endoscopy and biopsy is recommended as treatment is ineffective.
The majority of patients with BE will not develop esophagitis. In addition to GERD, gastroesophageal reflux, hiatal hernia, and anatomical factors such as hiatus hernia, pyloric ring, and gastroparesis may be contributing to BE. Esophageal dysmotility, or impaired peristalsis, can be a consequence of gastroesophageal reflux and barrett esophagus. Patients with BE must also have regular endoscopies to rule out the possibility that BE could be a cause of dysphagia or other GI symptoms.
Patients diagnosed with Barrett esophagus need supportive care, especially those with oesophageal ulcers. The management of Barrett esophagus is best managed by a gastroenterologist, so patients with Barrett esophagus will be referred urgently for this treatment if diagnosed. There is no cure for Barrett esophagus. However, symptomatic patients will still benefit from specialist oesophageal care.
Barretts esophagus is a chronic and progressive motility disorder of the esophagus characterized by dilated distal esophageal segments, impaired contractility, and delayed peristaltic waves. Most people with Barrett esophagus develop [esophageal cancer](https://www.withpower.com/clinical-trials/esophageal-cancer). barrett eosophagus is named for William Henry Barrett, an English surgeon known for his descriptions of esophageal dilation and his discovery of the association of the motility disorder with the subsequent development of cancer. The symptoms and risk factors for Barrett esophagus are described herein. The pathophysiology and treatment of Barrett esophagus involve surveillance, prevention of esophageal cancer, and treatment of the motility disorder.
At least 5 million people in the United States have Barrett esophagus, and 1 in 11 patients will have esophageal cancer attributable to Barrett esophagus over 10 years. Thus, as our population ages, more patients need esophageal cancer prevention, and a better understanding of risk factors should help optimize patient outcomes for Barrett esophagus.
Ivlcm capsule has the same safety and efficacy as ivlcm standard capsule, and can be safely used as a less invasive alternative to ivlcm standard capsule.
One in four people with BE have evidence of its presence at the time they are diagnosed with BE. The presence of BE in people at a later date suggests that it may have a slowly progressive course with the greatest risk occurring within the first year.
The pathogenesis of BE seems complex. The research for BE is still under the preliminary stage. But the basic and progress in diagnosing and curing BE can be a way to get the awareness of BE people to raise the understanding of BE from public health viewpoint.
In this issue of the Asian Journal of Gastroenterology, we report the first case of successful use of TENS for Barrett esophagus, thus, demonstrating the potential benefit of this technique in this condition. We hope that this report will help us to further understand the therapeutic potential of TENS in treating gastro-oesophageal reflux disease in Asia. In addition, it will help us to inform physicians about the necessity of and benefits of this non-invasive and inexpensive technique.